Post-discharge chemoprevention of malaria and other infections in children with severe anaemia

The UCT pharmacometrics group is involved in PDMC II, a trial investigating the use of Dihydroartemisinin piperaquine plus azithromycin for post-discharge chemoprevention of malaria and other infections in children with severe anaemia. The UCT pharmacometrics group designed the pharmacokinetic and pharmacodynamic sub study and are now overseeing the implementation of this part of the trial which is taking place in Malawi, Uganda and Kenya.